Ripretinib (DCC-2618)Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Bryan D. Smith, Michael D. Kaufman, Wei Ping Lu, Anu Gupta, Cynthia B. Leary, Scott C. Wise, Thomas J. Rutkoski, Yu Mi Ahn, Gada Al-Ani, Stacie L. Bulfer, Timothy M. Caldwell, Lawrence Chun, Carol L. Ensinger, Molly M. Hood, Arin McKinley, William C. Patt, Rodrigo Ruiz-Soto, Ying Su, Hanumaiah Telikepalli, Ajia TownBenjamin A. Turner, Lakshminarayana Vogeti, Subha Vogeti, Karen Yates, Filip Janku, Albiruni Ryan Abdul Razak, Oliver Rosen, Michael Heinrich, Daniel L. Flynn

    Research output: Contribution to journalArticle

    3 Citations (Scopus)

    Abstract

    Ripretinib (DCC-2618)was designed to inhibit the full spectrum of mutant KIT and PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in gastrointestinal stromal tumors (GISTs), in which the heterogeneity of drug-resistant KIT mutations is a major challenge. Ripretinib is a “switch-control” kinase inhibitor that forces the activation loop (or activation “switch”)into an inactive conformation. Ripretinib inhibits all tested KIT and PDGFRA mutants, and notably is a type II kinase inhibitor demonstrated to broadly inhibit activation loop mutations in KIT and PDGFRA, previously thought only achievable with type I inhibitors. Ripretinib shows efficacy in preclinical cancer models, and preliminary clinical data provide proof-of-concept that ripretinib inhibits a wide range of KIT mutants in patients with drug-resistant GISTs.

    Original languageEnglish (US)
    Pages (from-to)738-751.e9
    JournalCancer Cell
    Volume35
    Issue number5
    DOIs
    StatePublished - May 13 2019

    Fingerprint

    Gastrointestinal Stromal Tumors
    Phosphotransferases
    Pharmaceutical Preparations
    Neoplasms
    Mutation

    Keywords

    • conformational switch control
    • GIST
    • imatinib
    • KIT
    • mastocytosis
    • PDGFRA
    • regorafenib
    • resistance
    • ripretinib
    • sunitinib

    ASJC Scopus subject areas

    • Oncology
    • Cell Biology
    • Cancer Research

    Cite this

    Smith, B. D., Kaufman, M. D., Lu, W. P., Gupta, A., Leary, C. B., Wise, S. C., ... Flynn, D. L. (2019). Ripretinib (DCC-2618)Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell, 35(5), 738-751.e9. https://doi.org/10.1016/j.ccell.2019.04.006

    Ripretinib (DCC-2618)Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. / Smith, Bryan D.; Kaufman, Michael D.; Lu, Wei Ping; Gupta, Anu; Leary, Cynthia B.; Wise, Scott C.; Rutkoski, Thomas J.; Ahn, Yu Mi; Al-Ani, Gada; Bulfer, Stacie L.; Caldwell, Timothy M.; Chun, Lawrence; Ensinger, Carol L.; Hood, Molly M.; McKinley, Arin; Patt, William C.; Ruiz-Soto, Rodrigo; Su, Ying; Telikepalli, Hanumaiah; Town, Ajia; Turner, Benjamin A.; Vogeti, Lakshminarayana; Vogeti, Subha; Yates, Karen; Janku, Filip; Abdul Razak, Albiruni Ryan; Rosen, Oliver; Heinrich, Michael; Flynn, Daniel L.

    In: Cancer Cell, Vol. 35, No. 5, 13.05.2019, p. 738-751.e9.

    Research output: Contribution to journalArticle

    Smith, BD, Kaufman, MD, Lu, WP, Gupta, A, Leary, CB, Wise, SC, Rutkoski, TJ, Ahn, YM, Al-Ani, G, Bulfer, SL, Caldwell, TM, Chun, L, Ensinger, CL, Hood, MM, McKinley, A, Patt, WC, Ruiz-Soto, R, Su, Y, Telikepalli, H, Town, A, Turner, BA, Vogeti, L, Vogeti, S, Yates, K, Janku, F, Abdul Razak, AR, Rosen, O, Heinrich, M & Flynn, DL 2019, 'Ripretinib (DCC-2618)Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants', Cancer Cell, vol. 35, no. 5, pp. 738-751.e9. https://doi.org/10.1016/j.ccell.2019.04.006
    Smith, Bryan D. ; Kaufman, Michael D. ; Lu, Wei Ping ; Gupta, Anu ; Leary, Cynthia B. ; Wise, Scott C. ; Rutkoski, Thomas J. ; Ahn, Yu Mi ; Al-Ani, Gada ; Bulfer, Stacie L. ; Caldwell, Timothy M. ; Chun, Lawrence ; Ensinger, Carol L. ; Hood, Molly M. ; McKinley, Arin ; Patt, William C. ; Ruiz-Soto, Rodrigo ; Su, Ying ; Telikepalli, Hanumaiah ; Town, Ajia ; Turner, Benjamin A. ; Vogeti, Lakshminarayana ; Vogeti, Subha ; Yates, Karen ; Janku, Filip ; Abdul Razak, Albiruni Ryan ; Rosen, Oliver ; Heinrich, Michael ; Flynn, Daniel L. / Ripretinib (DCC-2618)Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. In: Cancer Cell. 2019 ; Vol. 35, No. 5. pp. 738-751.e9.
    @article{68af850a3c9c4f039fe7cdd2374c784f,
    title = "Ripretinib (DCC-2618)Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants",
    abstract = "Ripretinib (DCC-2618)was designed to inhibit the full spectrum of mutant KIT and PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in gastrointestinal stromal tumors (GISTs), in which the heterogeneity of drug-resistant KIT mutations is a major challenge. Ripretinib is a “switch-control” kinase inhibitor that forces the activation loop (or activation “switch”)into an inactive conformation. Ripretinib inhibits all tested KIT and PDGFRA mutants, and notably is a type II kinase inhibitor demonstrated to broadly inhibit activation loop mutations in KIT and PDGFRA, previously thought only achievable with type I inhibitors. Ripretinib shows efficacy in preclinical cancer models, and preliminary clinical data provide proof-of-concept that ripretinib inhibits a wide range of KIT mutants in patients with drug-resistant GISTs.",
    keywords = "conformational switch control, GIST, imatinib, KIT, mastocytosis, PDGFRA, regorafenib, resistance, ripretinib, sunitinib",
    author = "Smith, {Bryan D.} and Kaufman, {Michael D.} and Lu, {Wei Ping} and Anu Gupta and Leary, {Cynthia B.} and Wise, {Scott C.} and Rutkoski, {Thomas J.} and Ahn, {Yu Mi} and Gada Al-Ani and Bulfer, {Stacie L.} and Caldwell, {Timothy M.} and Lawrence Chun and Ensinger, {Carol L.} and Hood, {Molly M.} and Arin McKinley and Patt, {William C.} and Rodrigo Ruiz-Soto and Ying Su and Hanumaiah Telikepalli and Ajia Town and Turner, {Benjamin A.} and Lakshminarayana Vogeti and Subha Vogeti and Karen Yates and Filip Janku and {Abdul Razak}, {Albiruni Ryan} and Oliver Rosen and Michael Heinrich and Flynn, {Daniel L.}",
    year = "2019",
    month = "5",
    day = "13",
    doi = "10.1016/j.ccell.2019.04.006",
    language = "English (US)",
    volume = "35",
    pages = "738--751.e9",
    journal = "Cancer Cell",
    issn = "1535-6108",
    publisher = "Cell Press",
    number = "5",

    }

    TY - JOUR

    T1 - Ripretinib (DCC-2618)Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

    AU - Smith, Bryan D.

    AU - Kaufman, Michael D.

    AU - Lu, Wei Ping

    AU - Gupta, Anu

    AU - Leary, Cynthia B.

    AU - Wise, Scott C.

    AU - Rutkoski, Thomas J.

    AU - Ahn, Yu Mi

    AU - Al-Ani, Gada

    AU - Bulfer, Stacie L.

    AU - Caldwell, Timothy M.

    AU - Chun, Lawrence

    AU - Ensinger, Carol L.

    AU - Hood, Molly M.

    AU - McKinley, Arin

    AU - Patt, William C.

    AU - Ruiz-Soto, Rodrigo

    AU - Su, Ying

    AU - Telikepalli, Hanumaiah

    AU - Town, Ajia

    AU - Turner, Benjamin A.

    AU - Vogeti, Lakshminarayana

    AU - Vogeti, Subha

    AU - Yates, Karen

    AU - Janku, Filip

    AU - Abdul Razak, Albiruni Ryan

    AU - Rosen, Oliver

    AU - Heinrich, Michael

    AU - Flynn, Daniel L.

    PY - 2019/5/13

    Y1 - 2019/5/13

    N2 - Ripretinib (DCC-2618)was designed to inhibit the full spectrum of mutant KIT and PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in gastrointestinal stromal tumors (GISTs), in which the heterogeneity of drug-resistant KIT mutations is a major challenge. Ripretinib is a “switch-control” kinase inhibitor that forces the activation loop (or activation “switch”)into an inactive conformation. Ripretinib inhibits all tested KIT and PDGFRA mutants, and notably is a type II kinase inhibitor demonstrated to broadly inhibit activation loop mutations in KIT and PDGFRA, previously thought only achievable with type I inhibitors. Ripretinib shows efficacy in preclinical cancer models, and preliminary clinical data provide proof-of-concept that ripretinib inhibits a wide range of KIT mutants in patients with drug-resistant GISTs.

    AB - Ripretinib (DCC-2618)was designed to inhibit the full spectrum of mutant KIT and PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in gastrointestinal stromal tumors (GISTs), in which the heterogeneity of drug-resistant KIT mutations is a major challenge. Ripretinib is a “switch-control” kinase inhibitor that forces the activation loop (or activation “switch”)into an inactive conformation. Ripretinib inhibits all tested KIT and PDGFRA mutants, and notably is a type II kinase inhibitor demonstrated to broadly inhibit activation loop mutations in KIT and PDGFRA, previously thought only achievable with type I inhibitors. Ripretinib shows efficacy in preclinical cancer models, and preliminary clinical data provide proof-of-concept that ripretinib inhibits a wide range of KIT mutants in patients with drug-resistant GISTs.

    KW - conformational switch control

    KW - GIST

    KW - imatinib

    KW - KIT

    KW - mastocytosis

    KW - PDGFRA

    KW - regorafenib

    KW - resistance

    KW - ripretinib

    KW - sunitinib

    UR - http://www.scopus.com/inward/record.url?scp=85065013543&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85065013543&partnerID=8YFLogxK

    U2 - 10.1016/j.ccell.2019.04.006

    DO - 10.1016/j.ccell.2019.04.006

    M3 - Article

    C2 - 31085175

    AN - SCOPUS:85065013543

    VL - 35

    SP - 738-751.e9

    JO - Cancer Cell

    JF - Cancer Cell

    SN - 1535-6108

    IS - 5

    ER -